Lexaria Bioscience Corp. Common Stock

LEXX

Lexaria Bioscience Corp. (LEXX) is a technology company focused on developing and licensing proprietary drug delivery platforms that improve the bioavailability of orally consumed active compounds. Their innovations aim to enhance the absorption and effectiveness of pharmaceuticals and nutraceuticals, particularly in the sectors of cannabinoid and nicotine products. Founded with an emphasis on leveraging lipid-based technology, Lexaria aims to provide more efficient and safer delivery methods for various active ingredients.

$0.64 +0.06 (11.42%)
đźš« Lexaria Bioscience Corp. Common Stock does not pay dividends

Company News

Whoosh Wellness Launches Physician-Guided Telehealth Platform Offering Oral-First Wellness Protocols and Prescribed Microdosing Programs
GlobeNewswire Inc. • Not Specified • June 5, 2026

Whoosh Wellness, a new premium telehealth platform, launched with a focus on oral-first delivery formats for wellness protocols including semaglutide, tirzepatide, and other compounds. The platform differentiates itself through physician-prescribed microdosing approaches designed to minimize side effects while maintaining efficacy, targeting heal...

Why Asana Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Benzinga • Avi Kapoor • March 12, 2024

Shares of Asana, Inc. (NYSE: ASAN) fell sharply during Tuesday’s session following soft FY25 revenue guidance. Asana reported quarterly losses of 4 cents per share which beat the analyst consensus estimate of losses of 10 cents by 60%. Quarterly sales came in at $171.1 million, beating the analyst consensus estimate of $167.676 million by 2.04%...

Lexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Drug-Delivery System Improves Way Molecules Enter Bloodstream
GlobeNewswire Inc. • Lexaria Bioscience Corp. • January 11, 2024

NEW YORK, Jan. 11, 2024 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs.”

Lexaria Bioscience Corp. (NASDAQ: LEXX) Improves Delivery, Efficacy of GLP-1 Agonists Through Proprietary Drug-Delivery Platform
GlobeNewswire Inc. • Lexaria Bioscience Corp. • January 9, 2024

NEW YORK, Jan. 09, 2024 (GLOBE NEWSWIRE) -- via InvestorWire — Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 60+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and ...

Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating Proprietary Drug-Delivery Platform for Improved Efficacy of GLP-1 Drugs
GlobeNewswire Inc. • Lexaria Bioscience Corp. • October 31, 2023

NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) -- via InvestorWire — Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 60+ brands within the Dynamic Brand Portfolio @ IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news ...

Related Companies